Pharmasset, Inc – Product Pipeline Review – Q1 2011

Document Sample
Pharmasset, Inc – Product Pipeline Review – Q1 2011 Powered By Docstoc
					  Pharmasset, Inc – Product Pipeline Review – Q1 2011
                                                                                          Reference Code: GMDHC1260CDB

                                                                                                Publication Date: JUN 2011




Pharmasset, Inc – Product Pipeline Review – Q1 2011                                         GMDHC1260CDB / Published JUN 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Pharmasset, Inc – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        4
List of Figures                                                                                                       4
Pharmasset, Inc Snapshot                                                                                              5
    Pharmasset, Inc Overview                                                                                          5
    Key Information                                                                                                   5
    Key Facts                                                                                                         5
Pharmasset, Inc – Research and Development Overview                                                                   6
    Key Therapeutic Areas                                                                                             6
Pharmasset, Inc – Pipeline Review                                                                                     8
    Pipeline Products by Stage of Development                                                                         8
    Pipeline Products – Monotherapy                                                                                   9
    Pipeline Products – Combination Treatment Modalities                                                             10
Pharmasset, Inc – Pipeline Products Glance                                                                           11
    Pharmasset, Inc Clinical Stage Pipeline Products                                                                 11
         Phase II Products/Combination Treatment Modalities                                                          11
         Phase I Products/Combination Treatment Modalities                                                           12
    Pharmasset, Inc–Early Stage Pipeline Products                                                                    13
         Pre-Clinical Products/Combination Treatment Modalities                                                      13
Pharmasset, Inc – Drug Profiles                                                                                      14
    2-Fluoronucleosides                                                                                              14
         Product Description                                                                                         14
         Mechanism of Action                                                                                         14
         R&D Progress                                                                                                14
    PSI-7977 + Pegasys + Copegus                                                                                     15
         Product Description                                                                                         15
         Mechanism of Action                                                                                         15
         R&D Progress                                                                                                15
    Racivir                                                                                                          17
         Product Description                                                                                         17
         Mechanism of Action                                                                                         17
         R&D Progress                                                                                                17
    PSI-938                                                                                                          18
         Product Description                                                                                         18
         Mechanism of Action                                                                                         18
         R&D Progress                                                                                                18
    PSI-938 + PSI-7977                                                                                               19
         Product Description                                                                                         19
         Mechanism of Action                                                                                         19
         R&D Progress                                                                                                19
    2-Fluoronucleosides                                                                                              20
         Product Description                                                                                         20
         Mechanism of Action                                                                                         20
         R&D Progress                                                                                                20
    PSI-879                                                                                                          21
         Product Description                                                                                         21




Pharmasset, Inc – Product Pipeline Review – Q1 2011                                       GMDHC1260CDB / Published JUN 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
Pharmasset, Inc – Product Pipeline Review



         Mechanism of Action                                                                                              21
         R&D Progress                                                                                                     21
    PSI-938                                                                                                               22
         Product Description                                                                                              22
         Mechanism of Action                                                                                              22
         R&D Progress                                                                                                     22
Pharmasset, Inc – Pipeline Analysis                                                                                       23
    Pharmasset, Inc – Pipeline Products by Therapeutic Class                                                              23
    Pharmasset, Inc - Pipeline Products By Target                                                                         24
    Pharmasset, Inc – Pipeline Products by Route of Administration                                                        25
    Pharmasset, Inc – Pipeline Products by Molecule Type                                                                  26
Pharmasset, Inc – Recent Pipeline Updates                                                                                 27
Pharmasset, Inc - Dormant Projects                                                                                        29
Pharmasset, Inc - Discontinued Pipeline Products                                                                          30
    Discontinued Pipeline Product Profiles                                                                                30
         Clevudine                                                                                                        30
         Dexelvucitabine                                                                                                  30
Pharmasset, Inc – Locations And Subsidiaries                                                                              31
    Head Office                                                                                                           31
Financial Deals Landscape                                                                                                 32
    Pharmasset, Inc, Deals Volume Summary, 2004 to YTD 2011                                                               32
    Pharmasset, Inc, Deals Summary By Region, 2004 to YTD 2011                                                            33
    Pharmasset, Inc, Deals Summary, 2004 to YTD 2011                                                                      34
    Pharmasset, Inc Detailed Deal Summary                                                                                 35
         Acquisition                                                                                                      35
         CLP Power Acquires SPI Electricity & Gas And SPI Pipelines From SPI Australia Group                              35
         Meidensha Acquires Meiden Power Solutions                                                                        37
         Singapore Power Acquires TXU Australia From TXU                                                                  38
         Meidensha Corporation Acquires SP Systems From Singapore Power                                                   39
         Equity Offering                                                                                                  40
         Pharmasset Completes Public Offering Of Its Common Stock For $34 Million                                         40
         Pharmasset Completes Registered Direct Offering Of $46 Million                                                   42
         Pharmasset Completes Registered Direct Public Offering Of $26 Million                                            44
         Pharmasset Completes IPO For $45 Million                                                                         46
         Roche Signs An Agreement With Pharmasset                                                                         48
         Licensing Agreements                                                                                             49
         Pharmasset Enters Into Licensing Agreement With Bukwang Pharmaceutical                                           49
Appendix                                                                                                                  51
    Methodology                                                                                  
				
DOCUMENT INFO
Description: Pharmasset, Inc – Product Pipeline Review – Q1 2011 Summary Global Market Direct’s pharmaceuticals report, “Pharmasset, Inc - Product Pipeline Review - Q1 2011” provides data on the Pharmasset, Inc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Pharmasset, Inc’s corporate website, SEC filings, investor presentations and featured press releases, both from Pharmasset, Inc and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Pharmasset, Inc - Brief Pharmasset, Inc overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Pharmasset, Inc human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Pharmasset, Inc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Pharmasset, Inc’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Pharmasset, Inc’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Pharmasset, Inc in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Pharmasset, Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries